Biogazelle receives €499k Horizon 2020 funding to develop qPCR biomarker panels for multimorbidity associated with preterm birth
on August 12, 2019
Biogazelle announced today that it has been awarded €499K in funding from European commission under the Horizon 2020 - Research and Innovation Framework Programme. For the purposes of this investigation, Biogazelle will be the only SME in a consortium comprising 10 different organizations from 6 European countries.
With a duration of 5 years and a total budget of €6.5M, the miniNO project aims to identify the key causative mechanisms of the lifelong multimorbidity associated with preterm birth. miniNO will study for the first time the association between premature birth, alterations in mini-puberty and infantile nitric oxide (NO) signaling in the brain, and co-morbidities that appear later on in life. Biogazelle's contribution is centered around the design of qPCR assays to develop and validate 5 biomarker panels based on candidates identified both within as well as outside of the project.
"This grant award bears testament to the fact that Biogazelle's multi-year experience and successful track record in biomarker development and validation is widely acknowledged in the field" commented Jan Hellemans, Biogazelle CEO and co-founder. "The miniNO project promises the generation of new diagnostic and therapeutic tools that will ultimately improve the life of prematurely born individuals; we are hugely excited to be part of this ambitious endeavor."